Polyomaviruses
Polyomavirus JC
JC polyomavirus (JCV, JCPyV) is a small, non-enveloped DNA virus belonging to the family Polyomaviridae.

About the pathogen
JC polyomavirus (JCV, JCPyV) is a small, non-enveloped DNA virus belonging to the family Polyomaviridae. Primary infection most commonly occurs in childhood, usually asymptomatically, after which the virus persists in the body in a latent form, particularly in the renourinary tract and lymphoid cells. Infection is widespread in the general population. In the setting of significant impairment of cellular immunity, the virus may reactivate and spread to the central nervous system, where it can cause progressive multifocal leukoencephalopathy (PML), a severe demyelinating disease associated with progressive neurological impairment.
The risk of PML is increased particularly in immunocompromised patients and during certain immunosuppressive or immunomodulatory therapies, especially in patients with multiple sclerosis treated with natalizumab. Serological detection of anti-JCV IgG antibodies provides information on previous exposure to the virus. Anti-JCV serostatus and the antibody index are important parameters for PML risk stratification before and during natalizumab therapy. Serological results should always be interpreted in the context of the patient's clinical status and other risk factors.
VIDIA brings a unique solution for JCV serological diagnostics: ELISA-VIDITEST anti-JCV IgG enables the detection of specific anti-JCV IgG antibodies in human serum and plasma.
Portfolio
Available assays
FAQ
Frequently asked questions
What is JCV and why is it important in patients on natalizumab?
JC polyomavirus (JCPyV) is a common non-enveloped DNA virus that, after primary infection, enters latent persistence. In immunocompetent individuals it usually does not cause serious disease, but in the setting of impaired cellular immunity it can reactivate in the CNS and cause progressive multifocal leukoencephalopathy (PML). Natalizumab is a highly effective treatment for multiple sclerosis but is associated with a risk of PML. Key risk factors include anti-JCV antibody positivity, duration of natalizumab treatment, and prior immunosuppressive therapy. Determining anti-JCV antibodies is therefore part of PML risk stratification.
What does the anti-JCV antibody index mean and how is it used for PML risk stratification?
The anti-JCV antibody index expresses the relative intensity of the humoral response to JCV. In patients with no prior immunosuppressive therapy, it provides additional information on PML risk beyond seropositivity alone. In the European risk stratification used with natalizumab treatment, risk is lower at an index of 0.9 or below, while at a value above 1.5 it rises significantly, especially after more than 2 years of treatment. Values between 0.9 and 1.5 represent a transitional category and are always assessed together with treatment duration and immunosuppression history.
How often should serostatus be tested in patients on long-term natalizumab treatment?
According to EMA recommendations, anti-JCV status should be determined before starting treatment. Anti-JCV negative patients should be retested every 6 months. In patients with no prior immunosuppression and a low index, retesting every 6 months is recommended once 2 years of natalizumab treatment have been reached. Serostatus is dynamic, seroconversion can occur, and antibody response values can change over time. The result is therefore not a one-time, lifelong parameter.
What type of sample does the test require?
ELISA-VIDITEST anti-JCV IgG is intended for testing human serum or plasma.
How long does it take to get a result?
The ELISA-VIDITEST anti-JCV IgG protocol uses incubations of 60/60/10 minutes at room temperature, that is 130 minutes of incubation. After adding pipetting, washing and reading, the result is available within approximately one laboratory run lasting a little over two hours.
Cannot find what you are looking for?
Ask about a specific product
Send us a few lines about your case and we will reply with a recommendation within 24 hours.
Prefer not to use the form? Write directly to orders@vidia.cz
